Search

Author/Creator Serwatowski, Piotr

1. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Issue 4 (April 2022)

Authors:
Kindler, Hedy L; Novello, Silvia; Bearz, Alessandra; Ceresoli, Giovanni L; Aerts, Joachim G J V; Spicer, James; Taylor, Paul; Nackaerts, Kristiaan; Greystoke, Alastair; Jennens, Ross; Calabrò, Luana; Burgers, Jacobus A; Santoro, Armando; Cedrés, Susana; Serwatowski, Piotr; Ponce, Santiago; Van Me...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 4(2022)
Page Start:
540
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Issue 10 (November 2015)

Authors:
Gladkov, Oleg; Ramlau, Rodryg; Serwatowski, Piotr; Milanowski, Janusz; Tomeczko, Janusz; Komarnitsky, Philip B.; Kramer, Daniel; Krzakowski, Maciej J.
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 10(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer. Issue 10 (November 2015)

Authors:
Gladkov, Oleg; Ramlau, Rodryg; Serwatowski, Piotr; Milanowski, Janusz; Tomeczko, Janusz; Komarnitsky, Philip B.; Kramer, Daniel; Krzakowski, Maciej J.
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 10(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search